Boryung posted the best-ever quarterly sales in the second quarter of this year. Provisional figures, released by Boryung on July 27, showed that Boryung posted 172.2 billion won in Q2 sales and 14 billion won in Q2 operating profit.
The figures represent the best-ever business performance in Q2 and the best-ever sales over two quarters.
In particular, simultaneous growth in profitability and sales was significant. Boryung saw Q2 sales and Q2 operating profit surge 21.4 percent and 64.3 percent, respectively.
The good business performance was owed to the building of a stable revenue structure coupled with a product portfolio focusing on chronic disease prescription drugs and even growth of all business areas, including the recovery of commissioned businesses related to economic lead-off.
Boryung posted 342.7 billion won in sales and 32.7 billion won in operating profit in the first half of the year representing a 23 percent surge and a 47 percent jump, respectively.
In particular, Boryung plans to raise H2 sales and operating profit on the back of the release of new products, such as Dukarb + and the expanding of its product portfolio through legacy brand acquisition.
Boryung offers diverse treatment options based on the new Korea-made blood hypertension line-up, including Kanarb. The pharmaceutical company saw the Kanarb family line-up rake up 32.6 billion won in Q2 sales, a 21 percent year-on-year jump.
The release of the type 3 blood hypertension combination drug Dukarb+ in June is expected to see the Kanarb family expand its market share in the second half of the year.
The anticancer drug business saw its Q2 sakes soar 60 percent year-on-year to 36.4 billion won. Boryung, a drug maker with the nation’s biggest share in the anticancer drug market, has so far diversified its anticancer drug portfolio.
An image view of products, rolled out by Boryung. (Photo: Boryung)
Last year, Boryung began the exclusive sale of Samfenet and Onbevzitm, anticancer biosimilar drugs, released by Samsung Bioepis.
Boryung also began the joint sale of Grasin and Neulasta, the foreign and Korean market share No. 1 neutropenia drugs, with Kyowa Kirin Korea. Boryung saw Samfenet, Onbevzitm, Grasin and Neusta post 1.6 billion won, 4.5 billion won, 4.4 billion won and 8.7 billion won in sales, respectively.
The central nervous system drug business saw Q2 sales cruise on roll. The business saw Q2 sales jump 163 percent year-on-year to 15.6 billion won on the back of products, including the schizophrenia drug Zyprexa, acquired by Boryung through the legacy brand acquisition.
The diabetes drug Trulicity saw sales surge 19 percent year-on-year in the second quarter of the year.
The OTC drug Yonggaksan saw sales get a boost on the back of the COVID pandemic.
The drug saw Q2 sale jump 42 percent year-on-year to 3.6 billion won. It is expected to emerge as one of the pharmaceutical company’s blockbuster drugs.
Boryung President Jang Doo-hyun said, “Boryung will concentrate on building a strong revenue creation foundation through rising portion of items made on its own and the expanding of product portfolio, based on continued growth momentum.”
Boryung Obtains Product Approval for Zepzelca
Boryung obtained product approval for the small cell lung cancer new drug Zepzelca, developed by the Spanish drug maker PharmaMar S.A.
Zepzelca is a new anticancer drug developed by PharmaMar, and Boryung has the right to develop and sell the drug in Korea.
_보령제약 생산약품 이미지.jpg)
